Aptinyx looks to bring its NM­DA pipeline to Nas­daq, fil­ing for an $80 mil­lion IPO

A day af­ter Aptinyx closed an op­tion deal with Al­ler­gan for a small mol­e­cule de­pres­sion drug, the biotech hand­ed in its S-1, pen­cil­ing in an $80 mil­lion raise as it looks to join the IPO queue. If they make it, they will trade un­der the $AP­TX han­dle.

Run by CEO Nor­bert Riedel, Evanston, IL-based Aptinyx was spun out of the $1.7 bil­lion buy­out of Nau­rex — with $560 mil­lion in cash — which Al­ler­gan CEO Brent Saun­ders want­ed for its lead NM­DA drug aimed at ma­jor de­pres­sion. That drug is now dubbed ra­pastinel, which won a break­through drug des­ig­na­tion at the FDA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.